C-peptide levels do not correlate with pancreas allograft failure

Multicenter retrospective analysis and discussion of the new OPT definition of pancreas allograft failure

Silke V. Niederhaus, Robert J. Carrico, Matthew A. Prentice, Abigail C. Fox, Muhammad Mujtaba, Ty B. Dunn, Oyedolamu K. Olaitan, Jonathan S. Fisher, Robert J. Stratta, Alan C. Farney, Jon S. Odorico, Jonathan A. Fridell

Research output: Contribution to journalArticle

Abstract

The OPTN Pancreas Transplantation Committee performed a multicenter retrospective study to determine if undetectable serum C-peptide levels correspond to center-reported pancreas graft failures. C-peptide data from seven participating centers (n = 415 graft failures for transplants performed from 2002 to 2012) were analyzed pretransplant, at graft failure, and at return to insulin. One hundred forty-nine C-peptide values were submitted at pretransplant, 94 at return to insulin, and 233 at graft failure. There were 77 transplants with two available values (at pretransplant and at graft failure). For recipients in the study with pretransplant C-peptide <0.75 ng/mL who had a posttransplant C-peptide value available (n = 61), graft failure was declared at varying levels of C-peptide. High C-peptide values at graft failure were not explained by nonfasting testing or by individual center bias. Transplant centers declare pancreas graft failure at varying levels of C-peptide and do not consistently report C-peptide data. Until February 28, 2018, OPTN did not require reporting of posttransplant C-peptide levels and it appears that C-peptide levels are not consistently used for evaluating graft function. C-peptide levels should not be used as the sole criterion for the definition of pancreas graft failure.

Original languageEnglish (US)
JournalAmerican Journal of Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

C-Peptide
Allografts
Pancreas
Transplants
Insulin
Pancreas Transplantation
Multicenter Studies
Retrospective Studies

Keywords

  • clinical decision-making
  • clinical research/practice
  • complication: surgical/technical
  • endocrinology/diabetology
  • ethics and public policy
  • Organ Procurement and Transplantation Network (OPTN)
  • pancreas/simultaneous pancreas-kidney transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

C-peptide levels do not correlate with pancreas allograft failure : Multicenter retrospective analysis and discussion of the new OPT definition of pancreas allograft failure. / Niederhaus, Silke V.; Carrico, Robert J.; Prentice, Matthew A.; Fox, Abigail C.; Mujtaba, Muhammad; Dunn, Ty B.; Olaitan, Oyedolamu K.; Fisher, Jonathan S.; Stratta, Robert J.; Farney, Alan C.; Odorico, Jon S.; Fridell, Jonathan A.

In: American Journal of Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

Niederhaus, Silke V. ; Carrico, Robert J. ; Prentice, Matthew A. ; Fox, Abigail C. ; Mujtaba, Muhammad ; Dunn, Ty B. ; Olaitan, Oyedolamu K. ; Fisher, Jonathan S. ; Stratta, Robert J. ; Farney, Alan C. ; Odorico, Jon S. ; Fridell, Jonathan A. / C-peptide levels do not correlate with pancreas allograft failure : Multicenter retrospective analysis and discussion of the new OPT definition of pancreas allograft failure. In: American Journal of Transplantation. 2018.
@article{8a27f7a14ed642789ff8f4d9e1c2af47,
title = "C-peptide levels do not correlate with pancreas allograft failure: Multicenter retrospective analysis and discussion of the new OPT definition of pancreas allograft failure",
abstract = "The OPTN Pancreas Transplantation Committee performed a multicenter retrospective study to determine if undetectable serum C-peptide levels correspond to center-reported pancreas graft failures. C-peptide data from seven participating centers (n = 415 graft failures for transplants performed from 2002 to 2012) were analyzed pretransplant, at graft failure, and at return to insulin. One hundred forty-nine C-peptide values were submitted at pretransplant, 94 at return to insulin, and 233 at graft failure. There were 77 transplants with two available values (at pretransplant and at graft failure). For recipients in the study with pretransplant C-peptide <0.75 ng/mL who had a posttransplant C-peptide value available (n = 61), graft failure was declared at varying levels of C-peptide. High C-peptide values at graft failure were not explained by nonfasting testing or by individual center bias. Transplant centers declare pancreas graft failure at varying levels of C-peptide and do not consistently report C-peptide data. Until February 28, 2018, OPTN did not require reporting of posttransplant C-peptide levels and it appears that C-peptide levels are not consistently used for evaluating graft function. C-peptide levels should not be used as the sole criterion for the definition of pancreas graft failure.",
keywords = "clinical decision-making, clinical research/practice, complication: surgical/technical, endocrinology/diabetology, ethics and public policy, Organ Procurement and Transplantation Network (OPTN), pancreas/simultaneous pancreas-kidney transplantation",
author = "Niederhaus, {Silke V.} and Carrico, {Robert J.} and Prentice, {Matthew A.} and Fox, {Abigail C.} and Muhammad Mujtaba and Dunn, {Ty B.} and Olaitan, {Oyedolamu K.} and Fisher, {Jonathan S.} and Stratta, {Robert J.} and Farney, {Alan C.} and Odorico, {Jon S.} and Fridell, {Jonathan A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ajt.15118",
language = "English (US)",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - C-peptide levels do not correlate with pancreas allograft failure

T2 - Multicenter retrospective analysis and discussion of the new OPT definition of pancreas allograft failure

AU - Niederhaus, Silke V.

AU - Carrico, Robert J.

AU - Prentice, Matthew A.

AU - Fox, Abigail C.

AU - Mujtaba, Muhammad

AU - Dunn, Ty B.

AU - Olaitan, Oyedolamu K.

AU - Fisher, Jonathan S.

AU - Stratta, Robert J.

AU - Farney, Alan C.

AU - Odorico, Jon S.

AU - Fridell, Jonathan A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The OPTN Pancreas Transplantation Committee performed a multicenter retrospective study to determine if undetectable serum C-peptide levels correspond to center-reported pancreas graft failures. C-peptide data from seven participating centers (n = 415 graft failures for transplants performed from 2002 to 2012) were analyzed pretransplant, at graft failure, and at return to insulin. One hundred forty-nine C-peptide values were submitted at pretransplant, 94 at return to insulin, and 233 at graft failure. There were 77 transplants with two available values (at pretransplant and at graft failure). For recipients in the study with pretransplant C-peptide <0.75 ng/mL who had a posttransplant C-peptide value available (n = 61), graft failure was declared at varying levels of C-peptide. High C-peptide values at graft failure were not explained by nonfasting testing or by individual center bias. Transplant centers declare pancreas graft failure at varying levels of C-peptide and do not consistently report C-peptide data. Until February 28, 2018, OPTN did not require reporting of posttransplant C-peptide levels and it appears that C-peptide levels are not consistently used for evaluating graft function. C-peptide levels should not be used as the sole criterion for the definition of pancreas graft failure.

AB - The OPTN Pancreas Transplantation Committee performed a multicenter retrospective study to determine if undetectable serum C-peptide levels correspond to center-reported pancreas graft failures. C-peptide data from seven participating centers (n = 415 graft failures for transplants performed from 2002 to 2012) were analyzed pretransplant, at graft failure, and at return to insulin. One hundred forty-nine C-peptide values were submitted at pretransplant, 94 at return to insulin, and 233 at graft failure. There were 77 transplants with two available values (at pretransplant and at graft failure). For recipients in the study with pretransplant C-peptide <0.75 ng/mL who had a posttransplant C-peptide value available (n = 61), graft failure was declared at varying levels of C-peptide. High C-peptide values at graft failure were not explained by nonfasting testing or by individual center bias. Transplant centers declare pancreas graft failure at varying levels of C-peptide and do not consistently report C-peptide data. Until February 28, 2018, OPTN did not require reporting of posttransplant C-peptide levels and it appears that C-peptide levels are not consistently used for evaluating graft function. C-peptide levels should not be used as the sole criterion for the definition of pancreas graft failure.

KW - clinical decision-making

KW - clinical research/practice

KW - complication: surgical/technical

KW - endocrinology/diabetology

KW - ethics and public policy

KW - Organ Procurement and Transplantation Network (OPTN)

KW - pancreas/simultaneous pancreas-kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=85055283580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055283580&partnerID=8YFLogxK

U2 - 10.1111/ajt.15118

DO - 10.1111/ajt.15118

M3 - Article

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -